From monoclonal antibodies to chimeric antigen receptors for the treatment of human malignancies

Ignazio Caruana, Iulia Diaconu, Gianpietro Dotti

Research output: Contribution to journalArticlepeer-review

Abstract

Monoclonal antibodies (mAbs) and their directly derived cell-based application known as chimeric antigen receptors (CARs) ensue from the need to develop novel therapeutic strategies that retain high anti-tumor activity, but carry reduced toxicity compared to conventional chemo- and radiotherapies. In this concise review article, we will summarize the application of antibodies designed to target antigens expressed by tumor cells, and the transition from these antibodies to the generation of CARs.

Original languageEnglish
Pages (from-to)661-666
Number of pages6
JournalSeminars in Oncology
Volume41
Issue number5
DOIs
Publication statusPublished - Oct 1 2014

ASJC Scopus subject areas

  • Oncology
  • Hematology

Fingerprint Dive into the research topics of 'From monoclonal antibodies to chimeric antigen receptors for the treatment of human malignancies'. Together they form a unique fingerprint.

Cite this